Eisai's breast cancer drug ‘extends lives’
Washington, June 7, 2010
Eisai's experimental breast cancer drug eribulin added an average of two and a half months to the lives of patients dying of breast cancer, which is a big improvement in such seriously ill cancer patients, researchers said.
The results of the Phase III trial, presented to a meeting of the American Society of Clinical Oncology in Chicago, should change practice, conference organizers told reporters. – Reuters